olfactory receptor family 2 subfamily L member 5Genealiases: OR2L11 · OR2L5P
Q-omics provides the consensus-scored OR2L5 profile across patient tissues and cancer cell-line models. OR2L5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OR2L5 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, OR2L5 RNA expression shows 11,666 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where OR2L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2L5 survival associations across molecular data types. OR2L5 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2L5 RNA expression–survival associations across cancer types. High OR2L5 expression shows unfavorable associations in KIRP, LUSC, SARC, PRAD, HNSC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for OR2L5 RNA expression.
This table summarizes OR2L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2L5 shows lower tumor expression in UCEC and higher tumor expression in HNSC. The HNSC box plot shows higher OR2L5 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .009).
This table shows molecular features associated with OR2L5 in patient tissues and cancer cell lines. In patient samples, OR2L5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
